The Breakthrough Therapy Designation and clear regulatory path support upside potential ahead of topline data in Q2 2026, but investors should monitor execution risk and continued high burn rate. Insider buying suggests confidence in near-term catalysts.
LRMR drugs
LRMR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 19 $4.47entry
- T+1 · 8mo ago +0.45%α +2.19% · $4.49
- T+5 · 8mo ago +8.50%α +10.71% · $4.85
- T+20 · 7mo ago +7.38%α −0.24% · $4.80
- T+60 · 5mo ago −19.69%α −34.03% · $3.59
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Larimar Therapeutics reported Q4 and full-year 2025 financial results, highlighted by Breakthrough Therapy Designation from the FDA for nomlabofusp in Friedreich’s ataxia, a $107.6M public offering, and $244.5M in pro forma cash extending runway into Q2 2027. However, net losses widened significantly year-over-year due to increased R&D spending, particularly in manufacturing scale-up.
Key Financial Metrics
Key Facts
- FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, supporting accelerated approval pathway.
- BLA submission for nomlabofusp remains on track for June 2026, with U.S. launch targeted in first-half 2027 if approved.
- Topline data from open-label study expected in Q2 2026 to support BLA; global Phase 3 study to initiate screening in Q2 2026.
- Completed $115M public offering in February 2026, generating $107.6M in net proceeds.
- Pro forma cash, cash equivalents, and marketable securities totaled $244.5M as of December 31, 2025, extending cash runway into Q2 2027.
- Net loss for Q4 2025 was $62.5M vs. $28.8M in Q4 2024; full-year 2025 net loss was $165.7M vs. $80.6M in 2024.
- R&D expenses nearly doubled in 2025 to $154.2M from $73.3M in 2024, driven by $63.3M increase in nomlabofusp manufacturing costs.
Financial Impact
Significant increase in R&D spend ($154.2M in 2025) and net loss ($165.7M) year-over-year, offset by strong financing that boosted pro forma cash to $244.5M.
Risk Factors
- Clinical data from the open-label study in Q2 2026 may not support BLA approval despite FDA alignment.
- High R&D spend and increasing net losses raise long-term funding risks if commercialization is delayed.
- Dependence on accelerated approval pathway with FXN as a surrogate endpoint, which FDA may ultimately reject.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258845 |
Track record
13 reports on LRMR
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.13% at T+20 after the Sep 22, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $3.00 Now $3.00 0.00% settles Feb 12
- Nov 16, 2026today Press Release Bullish 7/10 Entry $3.10 Now $3.00 −3.23% settles Feb 12
- Nov 12, 20264d ago Insider Cluster Bullish 4/10 Entry $3.02 Now $3.00 −0.66% settles Feb 11
- Nov 9, 20267d ago 8-K Bullish 7/10 Entry $2.69 Now $3.00 +11.52% settles Feb 8
- Nov 5, 202611d ago Press Release Neutral 2/10 Entry $2.39 Now $3.00 +25.52% settles Feb 4
- Sep 29, 20266w ago Press Release Neutral 3/10 Entry $3.20 Now $3.00 −6.10% settles Dec 24
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $3.82 Now $3.00 +21.47% settles Dec 16
- May 14, 202626w ago 8-K Bullish 7/10 No price data
- May 14, 202626w ago Press Release Bullish 7/10 Entry $3.89 to $4.01 Now $3.00 −22.88% ▲ +3.08% −0.50% vs SPY
- Mar 19, 202634w ago Press Release Mixed 7/10 Viewing Entry $4.47 to $3.59 Now $3.00 −32.89% ▼ −19.69% −34.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers